Goldman Sachs Group Inc Unity Biotechnology, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

May 14, 2024
BUY
$0.4 - $4.27 $4,262 - $45,496
10,655 New
10,655 $4,000
Q3 2022

Nov 10, 2022
BUY
$0.4 - $4.27 $4,262 - $45,496
10,655 New
10,655 $0
Q2 2022

Aug 15, 2022
SELL
$0.56 - $1.29 $12,992 - $29,928
-23,200 Closed
0 $0
Q1 2022

May 16, 2022
SELL
$0.72 - $1.86 $48,214 - $124,553
-66,964 Reduced 74.27%
23,200 $26,000
Q4 2021

Feb 14, 2022
BUY
$1.3 - $3.17 $63,027 - $153,691
48,483 Added 116.32%
90,164 $132,000
Q3 2021

Nov 10, 2021
BUY
$2.91 - $4.5 $121,291 - $187,564
41,681 New
41,681 $125,000

Others Institutions Holding UBX

# of Institutions
1
Shares Held
4.41M
Call Options Held
0
Put Options Held
0
View Full List

About Unity Biotechnology, Inc.

UBX Quotes by TradingView
  • Ticker UBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,036,200
  • Market Cap $14M
  • Description
  • Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...
More about UBX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email